Disc Medicine’s (IRON) Buy Rating Reiterated at HC Wainwright

Disc Medicine (NASDAQ:IRON)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 52.14% from the stock’s previous close.

Several other equities analysts have also commented on the stock. Wells Fargo & Company assumed coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $57.00 target price on shares of Disc Medicine in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research note on Tuesday, October 15th. Scotiabank started coverage on Disc Medicine in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $62.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and an average price target of $66.40.

Disc Medicine Stock Up 0.0 %

IRON stock opened at $46.01 on Monday. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -13.61 and a beta of 0.59. The stock’s fifty day simple moving average is $48.92 and its 200-day simple moving average is $42.21. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.08. As a group, analysts anticipate that Disc Medicine will post -4.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Amalgamated Bank lifted its stake in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Disc Medicine in the 2nd quarter valued at about $129,000. SG Americas Securities LLC grew its position in shares of Disc Medicine by 44.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after buying an additional 1,247 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in Disc Medicine during the first quarter worth about $211,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.